Form 4: Vertex Pharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold shares of common stock under a pre-arranged trading plan.
Summary
- Ourania Tatsis, an executive at Vertex Pharmaceuticals, sold shares of the company's common stock on May 30 and May 31, 2024.
- The sales were executed under a company-approved trading plan (Rule 10b5-1) established on February 29, 2024.
- On May 30, 2024, 2,350 shares were sold at a price of $439.11 per share.
- On May 31, 2024, 2,250 shares were sold at a price of $445 per share.
- Following these transactions, Ms. Tatsis directly owns 51,273 shares of Vertex Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock sales by an executive. It doesn't contain information that would significantly shift investor sentiment.
Industry Context
Sales by executives are a normal part of corporate activity. The fact that the sale was executed under a 10b5-1 plan suggests that the executive planned the sales in advance.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date of entry into Rule 10b5-1 trading plan |
| 05/30/2024 | Date of first stock sale |
| 05/31/2024 | Date of second stock sale |
| 06/03/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.